The US Food and Drug Administration (FDA) granted approval for daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) to be used in combination with bortezomib, lenalidomide, and dexamethasone (VRd). This decision was based on data from the CEPHEUS trial, which included 395 patients who were either ineligible for or refused a transplant as their initial therapy.